Breakthrough Therapies: Another Drug’s Approval Should Not Lead To De Facto Rescission, Industry Says
Executive Summary
Industry and patient advocacy groups urge the agency to consider a variety of factors in determining whether a drug’s breakthrough designation should be rescinded upon the approval of another product; draft guidance language on quality of clinical evidence to be considered in rescission decisions raises concerns specific to rare disease populations.